University of Sussex – Translational Drug Discovery Group

The Translational Drug Discovery Group (TDDG) was established in 2011 as part of a strategic investment by the University of Sussex in the School of Life Sciences. The group comprises medicinal chemistry and molecular pharmacology laboratories and aims to translate a fundamental understanding of disease processes and molecular targets into novel drugs.  Research is currently focussed on:

Oncology – working with the Sussex Genome Damage & Stability Centre and external partners the group has a developing portfolio of novel programs targeting DNA damage repair targets.

Neuroscience – the group has a strong track record in neuroscience drug discovery and has several programs ranging from early hit to lead to late stage optimisation for indications including schizophrenia, pain and anxiety.

Respiratory –  activities are focused upon diseases associated with epithelial dysfunction including cystic fibrosis, COPD and asthma.

Ion channels – the group has considerable expertise in prosecuting ion channel targets and has specialist capabilities including electrophysiology and bespoke compound library generation.


Show full profile

Principal Disease Indication(s)

Oncology, Neuroscience, Respiratory


Platform(s)

Structure-based drug discovery, Ion channel modulators


Technology(ies):

Biophysical, X-ray crystallography, virtual screening, high-throughput electrophysiology, automated synthesis, medicinal chemistry


Funding sources:

Wellcome Trust, Cancer Research UK, Medical Research Council, EU, Migraine Research Foundation, Alzheimer’s Trust, Janssen, Evotec, Essen, Novartis


Personnel:

40


Number of Screens / year (any size):

4


Medicinal Chemistry Follow-up:

Yes


Contact Details

Dr Paul Beswick

Phone: +44 (0)1273 873 155
www.sussex.ac.uk

Contact Form

To contact us, please fill in the form below


Getting there

Address: Biology Road, Falmer, Brighton, The City of Brighton and Hove BN1, UK
X
- Enter Your Location -
- or -